<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539331</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00040</org_study_id>
    <nct_id>NCT00539331</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients</brief_title>
  <official_title>A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety &amp; Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of Pac/Carb Alone and in Combination With AZD2171 and Pac/Carb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has informed
      AstraZeneca that the BR24 Phase II/III study of cediranib at 30mg in first line non-small
      cell lung cancer (NSCLC) will not continue into Phase III following the planned end of Phase
      II efficacy and tolerability analysis by the study's Data Safety Monitoring Committee.
      Although evidence of clinical activity was seen, there appeared to be an imbalance in
      toxicity and therefore the study was considered not to have met the pre-defined criteria for
      automatic continuation into Phase III. As the design of Study 040 is similar to that of Study
      BR24, AstraZeneca has suspended recruitment into Study 040.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PART A : Safety and tolerability of AZD2171 in combination with pac/carbo in patients with non-small cell lung cancer</measure>
    <time_frame>Assessed at each visit during Part A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PART B : Assess the efficacy of AZD2171 by assessment of progression free survival (PFS)</measure>
    <time_frame>time to progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PART A : To examine the effect of AZD2171 on the PK of carboplatin and paclitaxel</measure>
    <time_frame>Assessed at each visit during Part A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B : To determine the efficacy of AZD2171 by assessment of overall response rate, change in tumour size and overall survival</measure>
    <time_frame>time to death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Paclitaxel/Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel/Carboplatin + AZD2171</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2171</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>2</arm_group_label>
    <other_name>cediranib</other_name>
    <other_name>RECENTIN™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>intravenous injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>CBDCA</other_name>
    <other_name>Paraplatin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having histologically or cytologically confirmed NSCLC

          -  Patients with previously untreated advanced/metastatic (Stage IIIB/IV) or postsurgery
             recurrent NSCLC

          -  WHO performance status 0-1

        Exclusion Criteria:

          -  Untreated unstable brain or meningeal metastases

          -  Patient with inappropriate laboratory tests values

          -  Patient with poorly controlled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masahiro Fukuoka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sakai hospital Kinki University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaojin Shin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>May 30, 2011</last_update_submitted>
  <last_update_submitted_qc>May 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jane Robertson, MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>AZD2171</keyword>
  <keyword>Paclitaxel/Carboplatin</keyword>
  <keyword>Non-small Cell Lung Cancer (NSCLC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

